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Large fraction radiation therapy offers a shorter course of treatment and radiobiological
advantages for prostate cancer treatment. The CyberKnife is an attractive technology for
delivering large fraction doses based on the ability to deliver highly conformal radiation
therapy to moving targets. In addition to intra-fractional translational motion (left–right,
superior–inferior, and anterior–posterior), prostate rotation (pitch, roll, and yaw) can increase
geographical miss risk.We describe our experience with six-dimensional (6D) intra-fraction
prostate motion correction using CyberKnife stereotactic body radiation therapy (SBRT).
Eighty-eight patients were treated by SBRT alone or with supplemental external radiation
therapy. Trans-perineal placement of four gold ﬁducials within the prostate accommo-
dated X-ray guided prostate localization and beam adjustment. Fiducial separation and
non-overlapping positioning permitted the orthogonal imaging required for 6D tracking.
Fiducial placement accuracy was assessed using the CyberKnife ﬁducial extraction algo-
rithm. Acute toxicities were assessed using Common Toxicity Criteria v3. There were no
Grade 3, or higher, complications and acutemorbidity wasminimal. Ninety-eight percent of
patients completed treatment employing 6D prostate motion tracking with intra-fractional
beam correction. Suboptimal ﬁducial placement limited treatment to 3D tracking in two
patients. Our experience may guide others in performing 6D correction of prostate motion
with CyberKnife SBRT.
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INTRODUCTION
Current radiation therapy options for treating clinically local-
ized prostate cancers include intensity-modulated radiation ther-
apy (IMRT), low-dose-rate (LDR) brachytherapy, high-dose-rate
(HDR) brachytherapy,proton beam therapy, and stereotactic body
radiation therapy (SBRT; Collins et al., 2011). Recent trends for
improving local control and patient quality of life, have focused
on dose escalation (Pollack et al., 2002; Zelefsky et al., 2002)
and on hypo-fractionation (Fowler, 2005; Miles and Lee, 2008).
Such treatment requires smaller treatment margins and greater
precision to limit geographic misses.
Technical factors of radiation delivery can contribute substan-
tially to local failure and excessive normal tissue toxicity. Patient
positioning errors and prostate motion limit the ability to accu-
rately deliver radiation therapy to the prostate. Pelvic immobi-
lization devices and daily set-up veriﬁcation decrease, but do not
eliminate, patient repositioning errors (Bentel et al., 1995). Due to
rectal and bladder ﬁlling, prostate gland position has been shown
to vary on a day-to-day basis (inter-fraction motion) and within
a treatment session (intra-fraction motion; Kupelian et al., 2008).
This motion is commonly largest in the anterior–posterior and
inferior–superior directions (Crook et al., 1995; Dawson et al.,
1998; Langen et al., 2008). To accommodate such uncertainties, a
0.5- to 1-cm margin is commonly added to the clinical treatment
volume (CTV, the prostate, and proximal seminal vesicles) to gen-
erate a planning treatment volume (PTV; Litzenberg et al., 2006).
The large size of this PTV margin, however, limits the extent of
safe dose escalation and hypo-fractionation (Pollack et al., 2002;
Zelefsky et al., 2002; Fowler, 2005; Miles and Lee, 2008).
Several prostate localization techniques have been utilized to
minimize PTV margins, including trans-abdominal ultrasound
(Chandra et al., 2003) and in-room kilovoltage CT (Moseley et al.,
2007). More commonly, intra-prostatic ﬁducial localization with
X-ray imaging is employed to correct for inter-fraction prostate
translations (inferior to superior, left to right, and anterior to
posterior; Kupelian et al., 2005). Fiducial migration during the
course of therapy is rare (Kupelian et al., 2005) and prostate
deformation is minimal (<1mm; Deurloo et al., 2005; Van Der
Wielen et al., 2008) making intra-prostatic ﬁducials an excellent
surrogate for prostate location. The technique offers the sig-
niﬁcant advantage of ease of use and reproducibility (Ullman
et al., 2006). Its implementation for daily isocenter localization
and set-up reduces required PTV margins (Litzenberg et al.,
2006). Correction of intra-fraction prostate translations further
decreases the requiredmargins to less than 3mm(Litzenberg et al.,
2006).
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In addition to prostate translational motion, prostate rota-
tion around the three translational axes (pitch, roll, and yaw;
Kaiser et al., 2006) can non-uniformly increase the required PTV
margins (Langer et al., 2005; Li et al., 2009). Rotational cor-
rections are especially important when the CTV includes the
seminal vesicles which can be signiﬁcantly under-dosed without
such corrections (Lips et al., 2009; Rijkhorst et al., 2009). Cur-
rently, most radiation delivery systems correct only for prostate
translations. While this may be acceptable when using large PTV
margins, failure to correct for rotations with the small PTV mar-
gins required for hypo-fractionation may result in under-dosing
of the CTV.
Hypo-fractionated SBRT using the CyberKnife (Accuray Incor-
porated, Sunnyvale, CA, USA) is a recent technical improvement
for treating clinically localized prostate cancer (Fuller et al., 2008;
Friedland et al., 2009; Katz et al., 2010b; Freeman and King,
2011; Oermann et al., 2011; Jabbari et al., in press; King et al.,
in press). In general, 35–40Gy is delivered to the prostate in
four to ﬁve fractions. CyberKnife SBRT precisely delivers highly
conformal radiation to theprostatewith six-dimensional (6D) cor-
rection of intra-fraction prostate motion (Xie et al., 2008; Kilby
et al., 2010). Orthogonal X-ray images are used to locate gold
ﬁducial markers within the prostate and allow for targeting and
correction of the therapeutic beam during an individual treat-
ment. Fiducials allow tracking and position correction of prostate
motion in 6D (Figure 1A). Here, we describe our experience with
6D correction of intra-fraction prostate motion with CyberKnife
SBRT.
MATERIALS AND METHODS
This is an Institutional IRB-approved retrospective review of 88
patients treated with SBRT with or without supplemental exter-
nal radiation therapy from July 2008 to July 2010. This analysis
was limited to patients whose ﬁducials were placed by the trans-
perineal approach. Fiducials were utilized for both SBRT and
conventional radiation therapy in patients receiving supplemen-
tal external radiation therapy (Katz et al., 2010a; Oermann et al.,
2010).
FIGURE 1 | (A)The 6D of possible prostate motion. The X -,Y -, and Z -axes
represent translational motion, while pitch, roll, and yaw represent rotation
around each of these axes. (B) Fiducial placement criteria for 6D tracking.
(1) A minimum of three ﬁducials are implanted within the prostate. (2) The
distance between any two ﬁducials must be greater than 20mm (Spacing
threshold). (3) All angles formed by the ﬁducial triplets must be greater than
15˚ (Co-linearity threshold).
TRANS-PERINEAL FIDUCIAL PLACEMENT
Fiducial implantation for CyberKnife prostate treatment is tech-
nically similar to ﬁducial placement for other forms of external
beam radiation therapy (Henry et al., 2004; Moman et al., 2010),
albeit with several key differences. A minimum of three ﬁducials
is required to employ 6D tracking.We observed early in our expe-
rience, based upon usage of the 6D tracking system, that ﬁducials
must be positioned with at least 2 cm of separation, to accommo-
date the ﬁducial spacing threshold; have at least 1 cm of separation
on orthogonal imaging to ensure accurate rotational corrections;
and that all angles formed by the ﬁducial triplets have to be greater
than 15˚ for the co-linearity threshold (Figure 1B). To optimize the
utility of the kilovoltage orthogonal X-ray images obtained during
treatment, we use gold (density equals 19.3 g/ml) ﬁducials (1013-
2-2, Best Medical International, Inc., Springﬁeld, VA, USA). Each
strand consists of two ﬁducials, each measuring 5mm by 0.8mm,
separatedby a 2-cmabsorbable strand tooptimizeﬁducial spacing.
Fiducials may be placed within the prostate via trans-rectal
or trans-perineal approaches. To improve the accuracy of ﬁducial
placement andminimize the risk of infection,weutilized the trans-
perineal approach. Prior to ﬁducial placement, prostate dimen-
sions, and volumes were determined using trans-rectal ultrasound
(TRUS; Littrup et al., 1991). Next, using real time TRUS guidance,
two sets of the stranded gold ﬁducials (a total of four ﬁdu-
cials), preloaded in 18 gage needles, were placed trans-perineally
into the prostate with the aid of a ﬁxed-frame guidance system
(Figures 2A–C). The ﬁducials were placed in the peripheral zone
at the left apex, right apex, left base, and right base to maximize
targeting accuracy of the prostate adjacent to the prostate rec-
tal interface. The median prostate length in this study was 4.7 cm
(Table 1) allowing for easy placement of the 3.0-cm strand. The left
and right needles were offset by 0.5 cm in the X -axis (Figure 2A)
to prevent overlap on orthogonal imaging. The procedure typi-
cally required 15min. Fiducial placement-related toxicities were
assessed using the Common Toxicity Criteria (CTC), version 3.
TREATMENT PLANNING
MRI and CT scans for treatment planning were performed 7 days
after ﬁducial implantation to ensure adequate tissue ﬁxation and
to allow for resolution of procedural edema/inﬂammation (Poggi
et al., 2003; Pouliot et al., 2003; Kupelian et al., 2005). Precautions
were taken tominimize prostatemotion during the planning scans
and treatment. Speciﬁcally, starting 5 days prior to acquisition of
Table 1 | Summary of the prostate size and number of fiducials
available for tracking.
Number of patients 88
Prostate dimensions Median Range
Height (mm) 29 14–60
Width (mm) 46 29–67
Length (mm) 47 30–69
Volume (mm3) 32 11.1–143
Number of ﬁducials available for tracking
3: 2 (2.3%) patients
4: 86 (97.7%) patients
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FIGURE 2 | Fiducial placement. (A) A ﬁxed-frame system with needles is
used to place ﬁducials under trans-rectal ultrasound guidance. (B) Axial and
(C) sagittal views of ultrasound image guidance.
the planning scans until the end of treatment, patients maintained
a low ﬁber diet to reduce intestinal gas (Smitsmans et al., 2008).
Fasts were also initiated 4 h before both acquisition of the planning
scans and each treatment session to minimize rectal movement.
Enemas were performed 2 h prior to acquisition of the planning
scans and each treatment session to minimize rectal volume. All
patients were imaged and treated in the supine treatment posi-
tion with a knee cushion to maximize patient comfort and limit
prostate motion in response to respiration (Malone et al., 2000).
Fused thin cut CT images (1.25mm) and high-resolution MR
images were used for treatment planning (Figures 3A–C). MRI
imaging was employed to deﬁne the target volume (Roach et al.,
1996) and to aid in accurate localization of the bladder neck,mem-
branous urethra, and penile bulb (Mclaughlin et al., 2005). Intra-
prostatic ﬁducials were employed to guide image co-registration
and limit fusion errors (Parker et al., 2003). MR images were
obtained on a 1.5-T scanner in a phased-array torso coil. TheMRI
was quickly (<1 h) followed by a CT scan to minimize anatomical
changes in the rectum that may interfere with image fusion. Two
MRI sequences were employed to maximize visualization of the
ﬁducials (susceptibility-weighted gradient-echo images) and the
soft tissues (axial high-resolution turbo T2-weighted spin-echo
images). Treatment planning included the prostate as the gross
target volume (GTV). The CTV included the prostate and the
proximal seminal vesicles. The PTV equaled the CTV expanded
by 3mm posteriorly and 5mm in all other dimensions. Treatment
planning was generally completed within 1week of imaging and
subsequent treatment was initiated within a 1- to 2-week window.
PRETREATMENT EVALUATION OF FIDUCIAL PLACEMENT
A minimum of three properly placed ﬁducials is required to
accommodate 6D tracking. Using the stranded ﬁducials, four ﬁdu-
cials are implanted which accommodates four separate ﬁducial
triplets, although only one triplet that meets threshold criteria
is required. The distances between individual ﬁducials (six lines)
were determined for each patient to assure that the ﬁducial spacing
threshold was met. Likewise, the angles formed by the triplets (12
angles) were determined to assure that the co-linearity threshold
was met. Results from a sample patient are shown in Table 2.
FIDUCIAL TRACKING
Fiducial markers were identiﬁed in the planning CT scan and the
image was converted into a digitally reconstructed radiograph
(DRR; Figures 4A,B, Synthetic image). The image registration
algorithm is based on alignment of the known DRR positions
with the marker locations extracted from the treatment orthogo-
nal X-ray images (Figures 4A,B, Camera image). An assessment of
potential marker migration is made automatically by determining
individual marker misalignment after registration (Figures 4A,B,
Overlay image). Small (<1mm) changes in ﬁducial position due
to prostate deformation (Deurloo et al., 2005; Van Der Wielen
et al., 2008) are allowed; however, changes in the individual ﬁducial
marker locations that exceed a 1-mm rigid body distance thresh-
old (Littrup et al., 1991) are assumed to have migrated from the
time of the treatment planning scans and are not used for guid-
ing treatment. The interval between successive image acquisitions
and alignment corrections is adapted throughout each treatment
fraction based on the intra-fraction stability of the target posi-
tion (translation) and orientation (rotation). The goals of ﬁducial
tracking are to keep the translational shifts to less than 2mm and
www.frontiersin.org December 2011 | Volume 1 | Article 48 | 3
Lei et al. 6D SBRT prostate motion correction
FIGURE 3 | Axial images through the mid-prostate. (A)Thin cut
CT scan visualizes ﬁducials well, but glandular tissue is indistinguishable
from adjacent soft tissues. (B) Long echo time axial 2DT1-weighted MR
images were obtained to optimally visualize ﬁducials. (C) Axial
high-resolution turboT2-weighted spin-echo MR images to assess prostatic
soft tissues.
Table 2 | Example of fiducial placement assessment.
A. Fiducial coordinates (mm)
Fiducials x y z
1 −5.8 22.6 362.3
2 −18.7 19.4 355.5
3 −2.3 12.1 343.9
4 −21.2 9.4 337.5
B. Distance between fiducials (mm)
1 2 3
1
2 15
3 21 21
4 32 21 20
C. Fiducial triplets Distances (mm) Angles (degrees)
a b c A B C
#1 (1,2,3) 15 21 21 69 70 41
#2 (1,2,4) 15 32 21 31 127 22
#3 (1,3,4) 21 32 20 38 101 41
#4 (2,3,4) 21 21 20 57 60 63
(A) The coordinates for the four implanted ﬁducials. (B) The calculated distances
between ﬁducials. (C) Assessment of four possible ﬁducial triplets. In this case,
the distance between ﬁducials 1 and 2 is less than the spacing threshold of 20mm
(bold).Thus, ﬁducial triplets #1 and #2 failed the spacing criteria. However, ﬁducial
triplets #3 (ﬁducials 1,3,4) and #4 (ﬁducials 2,3,4) exceeded both the spacing and
collinearity thresholds, thus allowing 6D target tracking.
the rotational shifts to less than 5˚ throughout treatment. In gen-
eral, imaging is obtained every 30–60 s to assure sub-millimeter
tracking accuracy (Xie et al., 2008). In the subset of patients with
a high frequency of excursions, the treating clinician is capable of
increasing the imaging frequency to maintain this accuracy.
RESULTS
From July 2008 to July 2010, 88 patients underwent trans-perineal
implantation of four gold ﬁducials using TRUS guidance at our
institution. Sixty-nine patients received CyberKnife SBRT alone
(total dose 35–36.25Gy delivered in ﬁve fractions) and 19 patients
received CyberKnife SBRT (total dose 19.5Gy delivered in three
fractions) followed by IMRT (total dose of 45–50.4Gy delivered
in 25–28 fractions). Each CyberKnife SBRT treatment was typi-
cally completed in 40–60min. The median prostate volume was
32 cc consistent with the patient population characteristics sum-
marized in Table 1. There was minimal acute toxicity following
the implantation procedure consisting primarily of grade 1 and 2
perineal pain lasting for 24–48 h which was relieved by mild anal-
gesics. No grade 3 or higher complications per the CTC v3 criteria.
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FIGURE 4 | Six-dimensional fiducial tracking for stereotactic body
radiation therapy with the CyberKnife system. Shown are digitally
reconstructed radiographs (left column), real time orthogonal X-ray images
(middle column), and co-registered overlay images (right column).
There were no post-implant urinary tract infections or episodes
of urinary retention.
Analysis of the treatment planning CT scans veriﬁed the pres-
ence of at least three ﬁducials in all cases. In two of the 88 patients,
a single ﬁducial was lost between the time of ﬁducial placement
and simulation (Table 1). Overall, 75% of the ﬁducial distances
exceeded the 2-cm ﬁducial spacing threshold and 98% of the ﬁdu-
cial angles exceeded the 15˚ co-linearity threshold. There were
no cases of ﬁducial overlap on orthogonal imaging. In 98% of
cases, at least one ﬁducial triplet met the criteria for 6D correc-
tion of prostate motion. In two patients, all four possible ﬁducial
triplets failed the spacing and/or collinearity threshold. As a result,
CyberKnife treatment was limited to 3D tracking for those two
patients. Fiducial tracking was also utilized for patient set-up in 19
patients treated in combination with conventional external beam
radiation therapy.
DISCUSSION
The ability of dose escalation to improve disease control in clin-
ically localized prostate cancer has been supported by several
clinical studies and is accepted as a goal in prostate cancer treat-
ment (Pollack et al., 2002; Fowler, 2005; Miles and Lee, 2008).
A concern with dose escalation, however, is the possibility of
increasing acute and late toxicities. For this reason, PTV mar-
gins are typically minimized thereby limiting dose to surrounding
normal tissues (Dearnaley et al., 2007). Reduced PTV margins
require accurate beampositioning and veriﬁcation to ensure deliv-
ery of the planned dose to the target. Fiducials are accurate and
reproducible surrogates for prostate location and allow for cor-
rection of both inter-fraction and intra-fraction prostate motions
(Deurloo et al., 2005; Kupelian et al., 2005; Van Der Wielen et al.,
2008). High-dose IMRT using ﬁducial-based correction of trans-
lational motion prior to treatment is well tolerated with a low
incidence of acute and late gastrointestinal and genitourinary
side effects (Lips et al., 2008). Such positional veriﬁcation also
allows the delivery of increased radiation doses without deteri-
oration in quality of life compared with lower doses using less
accurate conformal radiotherapy (Lips et al., 2007). Early results
with CyberKnife SBRT suggest that the addition of 6D correction
of intra-fraction prostate motion allows hypo-fractionated radio-
biologic dose escalation while maintaining quality of life (Fuller
et al., 2008; Friedland et al., 2009; Katz et al., 2010b; Freeman and
King, 2011; Oermann et al., 2011; Jabbari et al., in press; King et al.,
in press).
The optimal number and location of implanted markers for
image guided radiation therapyhas been investigated (Kudchadker
et al., 2009). In previous studies,one to six ﬁducialswere implanted
(Poggi et al., 2003; Henry et al., 2004; Moman et al., 2010). At least
three properly positioned ﬁducials are required for translational
and rotational correction with the CyberKnife system. Thus, we
placed four ﬁducials to allow for possible loss/migration of one
ﬁducial; an event that occurred in two of our patients. It is unclear
whether the accuracy of targeted radiation therapy is improved by
placing additional ﬁducials. However, placement of greater than
four ﬁducials may increase the risk of ﬁducial mis-identiﬁcation
due to their close proximity (Mu et al., 2008).
Intra-fractional motion correction should accommodate fur-
ther investigational dose escalation by limiting dose to normal
structures. Two strategies currently exist for dealing with intra-
fraction motion: reducing treatment times and/or performing
continuous tracking during treatment. It is well known that the
extent of intra-fractionmotion increases with increasing duration
of treatment (Ghilezan et al., 2005; Kotte et al., 2007; Langen et al.,
2008). Rotational therapy, such as volumetric modulated arc ther-
apy (VMAC) or RapidArc (VarianMedical Systems, Palo Alto, CA,
USA), can reduce treatment times to just a few minutes (Wolff
et al., 2009; Aznar et al., 2010) possibly decreasing the impact
of intra-fraction motion. Unfortunately, large prostate motions
are not predictable and commonly occur early in the course of
a treatment (Langen et al., 2008). While ignoring intra-fraction
motion may be acceptable with extended fractionation regimens
due to intra-fraction motion’s random nature, failure to account
for intra-fraction motion may lead to clinically meaningful errors
with hypo-fractionated regimens (Hoogeman et al., 2008) where
small prostate dose decrements could bemore clinically signiﬁcant
(Craig et al., 2003).
The added beneﬁt of correcting for rotational movement is
the subject of investigation (Mutanga et al., 2011). Some argue
that small deformations interpreted as rotations could actually
increase the risk of geometric miss (Wu et al., 2007). The smaller
treatment margins required for hypo-fractionation increase the
importance of correcting for even small treatment errors. The
appropriate PTVmargins necessary to accommodate rotations are
both challenging to determine and likely patient speciﬁc (Langer
et al., 2005) making them difﬁcult to apply in the clinical setting.
Intra-fractional rotational correction eliminates the need for these
complex and potentially large PTV expansions.When treating the
prostate alone, the target volume approximates a sphere making
rotational correction likely of little beneﬁt. However, when the
target volume is the prostate and the proximal seminal vesicle,
rotational corrections may be important to prevent under-dosing
of the seminal vesicles (Lips et al., 2009; Rijkhorst et al., 2009).
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CONCLUSION
Hypo-fractionated SBRT with 6D correction of prostate motion
is a promising new treatment option for men with low- and
intermediate-risk prostate cancer. Early results suggest encourag-
ing biochemical responses with low toxicities (Fuller et al., 2008;
Friedland et al., 2009; Katz et al., 2010b; Freeman and King,
2011; Oermann et al., 2011; Jabbari et al., in press; King et al.,
in press). 6D correction of intra-fraction prostate motion may
be critical to obtaining such outcomes. Our experience shows
that with accurate ﬁducial placement, 6D correction of prostate
motion with CyberKnife SBRT is feasible in the majority of
patients. Investigation of additional patients with longer follow-
up will be required to validate the clinical beneﬁts of such an
approach.
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